One-Pot Covalent Grafting of Gelatin on Poly(Vinyl Alcohol) Hydrogel to Enhance Endothelialization and Hemocompatibility for Synthetic Vascular Graft Applications

• Published in: ACS applied bio materials Vol. 3; no. 1; pp. 693 - 703
• Main Authors: Rizwan, Muhammad, Yao, Yuan, Gorbet, Maud B, Tse, John W, Anderson, Deirdre E. J, Hinds, Monica T, Yim, Evelyn K. F
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 21-01-2020
• Subjects: endothelial adhesion; hemocompatibility; thrombogenesis; surface modification; blood clotting; anticoagulation
• ISSN: 2576-6422; 2576-6422
• DOI: 10.1021/acsabm.9b01026

Cardiovascular diseases remain the leading cause of death worldwide. Patency rates of clinically utilized small diameter synthetic vascular grafts, such as Dacron and expanded polytetrafluoroethylene (ePTFE), to treat cardiovascular disease are inadequate because of the lack of endothelialization. Sodium trimetaphosphate (STMP) cross-linked poly­(vinyl alcohol) (PVA) could be potentially employed as blood-compatible small diameter vascular graft for the treatment of cardiovascular disease. However, PVA severely lacks cell adhesion properties, and the efforts to endothelialize STMP-PVA have been insufficient to produce a functioning endothelium. To this end, we developed a one-pot method to conjugate cell-adhesive protein via hydroxyl-to-amine coupling using carbonyldiimidazole by targeting residual hydroxyl groups on cross-linked STMP-PVA hydrogel. Primary human umbilical vascular endothelial cells (HUVECs) demonstrated significantly improved cells adhesion, viability, and spreading on modified PVA. Cells formed a confluent endothelial monolayer, and expressed vinculin focal adhesions, cell–cell junction protein zonula occludens 1 (ZO1), and vascular endothelial cadherin (VE-Cadherin). Extensive characterization of the blood-compatibility was performed on modified PVA hydrogel by examining platelet activation, platelet microparticle formation, platelet CD61 and CD62P expression, and thrombin generation, which showed that the modified PVA was blood-compatible. Additionally, grafts were tested under whole, flowing blood without any anticoagulants in a nonhuman primate, arteriovenous shunt model. No differences were seen in platelet or fibrin accumulation between the modified-PVA, unmodified PVA, or clinical, ePTFE controls. This study presents a significant step in the modification of PVA for the development of next generation in situ endothelialized synthetic vascular grafts.